MJRX.CN Global Health Clinics (CNQ) -41% 03 Feb 2026: Support near C$0.03

MJRX.CN stock plunged 41.67% during market hours to C$0.035 on 03 Feb 2026. The drop follows a sharp intraday reversal from an open of C$0.06, with volume at 24,100.00 shares, nearly four times the average of 5,613.00. Investors are watching support near the year low of C$0.01 and resistance near the day high of C$0.06. This piece looks at fundamentals, technicals, Meyka AI grading, and a short-term forecast to frame risk and potential reward for Global Health Clinics Ltd. (MJRX.CN) on the CNQ in Canada.

MJRX.CN stock: price action and immediate drivers

Global Health Clinics Ltd. (MJRX.CN) fell to C$0.035 after opening at C$0.06. The intraday move shows sellers dominating despite a 50-day average of C$0.03. Volume spiked to 24,100.00, giving a relative volume of 4.29. One visible driver is thin market liquidity and negative sentiment in small-cap cannabis names during market hours on CNQ. The day low matched C$0.035, while the year high remains C$0.09.

MJRX.CN stock: fundamentals and valuation snapshot

Key metrics show stress: market cap C$328,725.00, EPS -0.14, and PE -0.25. Price-to-sales is 10.73, and enterprise value is C$2,374,459.00. Current ratio sits at 0.01, indicating tight liquidity. Revenue per share is 0.00(3), and book value per share is -0.52. These figures point to high valuation pressure versus Healthcare sector averages, where the sector PE is about 14.24.

MJRX.CN stock: technical picture and short-term levels

Momentum indicators show mixed signals with RSI 47.29 and ADX 32.16, which suggests a strong trend. Bollinger bands are 0.01–0.06, with the middle band at 0.03. Immediate support is the year low C$0.01 and a short-term support zone near C$0.03. Resistance lies at the open and day high C$0.06 and the 50-day average C$0.03. Watch volume and an RSI break above 55.00 for any recovery attempt.

Meyka AI grade and analyst context for MJRX.CN stock

Meyka AI rates MJRX.CN with a score out of 100: 67.31 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. External analyst data shows a company rating of C with a Sell recommendation dated 2026-01-26. Investors should treat both internal and external ratings as inputs, not investment advice, and weigh liquidity risk and small-cap volatility.

MJRX.CN stock: risks, catalysts and sector context

Primary risks include weak liquidity, negative EPS, and a low current ratio of 0.01. Catalysts would be clinical or regulatory updates on psilocybin research and stronger patient clinic revenues. Within Healthcare, small cannabis and specialty drug names face tougher funding and higher volatility than sector peers. Compare competitor moves at Investing.com comparison and company filings at the corporate site Global Health Clinics.

Final Thoughts

MJRX.CN stock is trading at C$0.035 on 03 Feb 2026 after a steep intraday fall of 41.67%. The company shows stressed fundamentals, including EPS -0.14, PE -0.25, and a thin current ratio 0.01, which supports a cautious stance. Near-term technical support sits at C$0.03 and the year low C$0.01. Meyka AI’s forecast model projects a monthly price near C$0.04, implying a short-term upside of 14.29% versus the current price. That forecast is model-based and not a guarantee. Given the external company rating of C (Sell) and Meyka AI’s B/HOLD grade, investors should prioritise risk management. For traders, look for a confirmed volume-led reversal and a close above C$0.06 before considering any position. For longer-term holders, monitor cash runway, clinic revenue trends, and any psilocybin research milestones. Meyka AI provides this as data-driven market analysis, not personalised advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.